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Abstract
Background: The growing advances in DNA sequencing tools have made analyzing the human genome cheaper
and faster. While such analyses are intended to identify complex variants, related to disease susceptibility and
efficacy of drug responses, they have blurred the definitions of mutation and polymorphism.
Discussion: In the era of personal genomics, it is critical to establish clear guidelines regarding the use of a
reference genome. Nowadays DNA variants are called as differences in comparison to a reference. In a sequencing
project Single Nucleotide Polymorphisms (SNPs) and DNA mutations are defined as DNA variants detectable
in >1 % or <1 % of the population, respectively. The alternative use of the two terms mutation or polymorphism
for the same event (a difference as compared with a reference) can lead to problems of classification. These
problems can impact the accuracy of the interpretation and the functional relationship between a disease state
and a genomic sequence.
Summary: We propose to solve this nomenclature dilemma by defining mutations as DNA variants obtained in a
paired sequencing project including the germline DNA of the same individual as a reference. Moreover, the term
mutation should be accompanied by a qualifying prefix indicating whether the mutation occurs only in somatic
cells (somatic mutation) or also in the germline (germline mutation). We believe this distinction in definition will
help avoid confusion among researchers and support the practice of sequencing the germline and somatic
tissues in parallel to classify the DNA variants thus defined as mutations.
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Background
The human genome consists of over 3 billion base pairs
which reside in every nucleated cell of the body [1, 2].
The genome, which has remained well conserved
throughout evolution, is at least 99.5 % identical be-
tween any two humans on the planet [3]. Modern
genomic tools have revealed that it is more complex,
diverse, and dynamic than previously thought, even
though the genetic variation is limited to between
0.1 % [4–6] and 0.4 % [7] of the genome. Sequence
variations, even in non-protein coding regions of the
DNA, have begun to alter our understanding of the
human genome. While some studies have linked cer-
tain variants to being predictive of disease susceptibil-
ity and drug response, the majority of diseases have a
very complex genetic signature (reviewed in [8, 9]).
Biomedical research is shifting towards understanding
the functional importance of many such variations
and their association with human diseases.
At the heart of these novel discoveries are the modern
DNA sequencing tools, which continue to evolve at a
rapid pace. The new sequencing technologies continue to
become cheaper and more precise, and facilitate novel
medical and biological breakthroughs all over the world
[10, 11]. Scientific research has become nearly incon-
ceivable without employing sequencing technology
but, with the progress of technology and the increas-
ing sequencing of individuals, a massive amount of
data is being generated. However, any data without
context and analysis is useless. The data from sequen-
cing must be carefully annotated, securely stored, and
easily accessible from repositories when needed. Such
arduous tasks require functional collaboration among
clinicians, researchers, and health professionals [12].
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In a recent thread in the ResearchGate portal [13], an
ongoing discussion on the difference between a muta-
tion and a polymorphism elicited a response from more
than three hundred participants from various scientific
backgrounds. The variety of responses prompted us to
write this document as a paper aimed at stimulating
the discussion further and possibly finding a consen-
sus on the usage of the terms mutation and poly-
morphism in the context of a reference sequence in a
personal genome project.
Discussion
The rise of genomics and its impact on human health
Established in 1990, the Human Genome Project was
one of the most expensive and collaborative ventures
ever undertaken in science. Ten years since its comple-
tion, it has continued to provide a wealth of novel in-
formation, the implications of which are not yet fully
understood [8]. The open-access nature of the project
has stimulated scientists, as well as scientific companies,
to develop better sequencing tools and accompanying
analytical software. The ensuing innovations have helped
to mark down the price of whole genome sequencing
over the years, from nearly $3 billion at its inception to
under $3,000, making it accessible to researchers from
different biomedical disciplines [14].
Sequencing tools will play an important role in the de-
velopment of personalized medicine. Some sequencing
technologies are already used in clinics to test genetic
conditions, diagnose complex diseases, or screen patient
samples for rare variants. These tests allow health pro-
fessionals to accurately diagnose a disease and prescribe
appropriate medication specific to the patient [15, 16].
With the recent support of NIH grants in the US, neo-
natal sequencing is being explored to probe rare and
complex disorders of newborn babies [17, 18]. There are
technologies in development that allow non-invasive
ways of sequencing a genome of an unborn child [19].
Personalized genome sequencing will transform the
future of the healthcare landscape. However, the rise in
the number of sequenced genomes is creating new pro-
blems. In particular, the way the genome analysis soft-
ware works is through comparison of the obtained
sequences with a reference. Because the human genome
is different between different individuals, what is the
reference sequence? What is the threshold to distinguish
common from rare DNA variants?
Amid all these interesting implications of genome se-
quencing, the debate concerning the correct use of scien-
tific terminology remains. Specifically, the nomenclature
“mutation” and “polymorphism”, and also “point muta-
tion” versus “SNP”, can be independently used to describe
the same event, namely a difference in the sequence as
compared with a reference. From a strictly grammatical
and etymological point of view, a mutation is an
event (of mutating) and a polymorphism is a condi-
tion or quality (of being polymorphic); but these
terms by extension quickly came to mean the result-
ing event or condition itself. In principle, a point
DNA variant can be labeled as a mutation or SNP.
Since no clear rules are available, currently used soft-
ware tools used for genome sequencing make no as-
signment and label the difference simply as DNA
variant, blurring the distinction between the two
categories.
“Mutation” and “polymorphism”: earlier definitions
The uniform and unequivocal description of sequence var-
iants in human DNA and protein sequences (mutations,
polymorphisms) were initiated by two papers published in
1993 [20, 21]. In this context, any rare change in the nu-
cleotide sequence, usually but not always with a disease
causing attribute, is termed a “mutation” [22]. This change
in the nucleotide sequence may or may not cause pheno-
typic changes. Mutations can be inherited from parents
(germline mutations) or acquired over the life of an indi-
vidual (somatic mutations), the latter being the principal
driver of human diseases like cancer. Germline mutations
occur in the gametes. Since the offspring is initially de-
rived from the fusion of an egg and a sperm, germline mu-
tations of parents may also be found in each nucleated cell
of their progeny. Mutations usually arise from unrepaired
DNA damage, replication errors, or mobile genetic ele-
ments. There are several major classes of DNA mutations.
A point mutation occurs when a single nucleotide is
added, deleted or substituted. Along with point mutations,
the whole structure of a chromosome can be altered, with
chromosomal regions being flipped, deleted, duplicated,
or translocated [23]. Another kind of DNA mutation is
defined as “copy number variation”. In this case, the ex-
pression of a gene is amplified (or reduced) through in-
creased (decreased) copy number of a locus allele [24, 25].
A variation in the DNA sequence that occurs in a
population with a frequency of 1 % or higher is termed a
polymorphism [26]. The higher incidence in the popula-
tion suggests that a polymorphism is naturally occurring,
with either a neutral or beneficial effect. Polymorphisms
can also be of one or more nucleotide changes, just like
mutations. The SNP exemplifies the commonest poly-
morphism, thought to arise every 1,000 base pairs in the
human genome, and is usually found in areas flanking
protein-coding genes [27] – regions now recognized
as critical for microRNA binding and regulation of
gene/protein expression [28]. However, SNPs can also
occur in coding sequences, introns, or in intergenic re-
gions [27]. SNPs are used as genetic signatures in popula-
tions to study the predisposition to certain traits,
including diseases [29].
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The anatomy of the problem
In the era of advanced DNA sequencing tools and
personal genomics, these earlier definitions of mutation
and polymorphism are antiquated. Before multiple
parallel sequencing was developed, it was impossible to
sequence multiple times the genome of the same
patient. For these reasons at that time it was required
to use a reference sequence coming from the assembly
of multiple genomes. In the preparation of the consen-
sus sequence, an arbitrary threshold of 1 % was estab-
lished to distinguish common (polymorphism) from
rare (mutation) variants [26].
The 1 % or higher frequency associated with a poly-
morphism is an arbitrary number [30] recommended
by scientists prior to the era of Next Gen Sequencing.
The threshold being arbitrary, redefining the popula-
tion itself may affect the classification, with rare
variants becoming polymorphisms or polymorphisms
becoming rare variants according to the population
analyzed. For decades, the use of this frequency to
develop population models was preferred to the use
of sequencing tools, which at that time were error-
prone and labor-intensive. With the advent of new se-
quencing technologies and the subsequent sequencing
of individuals, a very different picture of population
dynamics has begun to emerge. Mutations that were
thought to be rare in a population have been found
to exceed the frequency threshold set at 1 % [31].
Even more surprising, there is a lack of association of
some of these rare mutations with human diseases.
When comparing populations separated by geographic
and physical barriers, a disease-causing mutation in
one population is found to be harmless in another,
and vice versa [32].
For instance, sickle-cell anemia is caused by a nucleo-
tide change (SNP rs334) in a gene coding for the beta
chain of the hemoglobin protein [33]. In fact, rs334 is
classified as a SNP, since its minor allele frequency in
the population is >1 %. The disease manifests in people
who have two copies of the mutated gene (rs334(T;T)
genotype). Sickle cell anemia is usually rare (<1 %) in the
populations of developed nations [34]. However, the
heterozygous form of the gene (rs334(A;T) genotype) is
persistent in populations of Africa, India, and other de-
veloping nations, where malaria is endemic [33]. In these
geographic locations, heterozygote carriers of rs334 have
a survival advantage against the malaria pathogen, and
therefore this beneficial mutation is passed through the
offspring to succeeding generations [35–37]. Here, a rare
variant, which in one population (developed nations)
causes a severe disease in homozygosis, can persist in
another population to confer a survival advantage as a
polymorphism in heterozygosis [38]. Such exceptions are
increasing and show the need to redefine the terms
mutation and polymorphism. The distinction between
mutation and polymorphism on the basis of their
disease-causing capacity is further complicated. Al-
though thought to be naturally occurring, recent re-
search into SNPs has shown that they can be associated
with diseases like diabetes and cancers. At least 40 SNPs
have been shown to associate with type-2 diabetes alone
[39]. In short, it is not possible to classify the functional
role of variations according to frequency in the popula-
tion or their capability to cause a disease.
Context of personal genomics
This debate on “mutation” and “polymorphism” needs
urgent evaluation in the era of Next Gen Sequencing
and precision medicine. Multiple international collabora-
tive projects like ENCODE (Encyclopedia of DNA ele-
ments) and HapMap (Haplotype Map) have ensued to
map all the genes, genetic variation, and regulatory ele-
ments of the genome, to find associations with human
biology, personal traits, and diseases [40].
In this climate, commercial companies like Illumina
and Roche are developing advanced and robust plat-
forms that tailor to the need of both small and large
research facilities. The increasing competition among
these companies has resulted in many different tech-
nologies, which are now available to facilitate new
insights into genomics [11]. Similarly, advanced genomic
tools and analytical software have been developed that
can function independently of the particular platform.
Researchers using tools like CLC genomics, Next Gene
and Geno Matrix, can access and download sequencing
datasets for their own streamlined research. The primary
goal of such research is to look for subtle, complex, and
dynamic sequence variations. The lack of consistent defi-
nitions and a uniform scientific language can hamper
this upcoming field, where genomic platforms may for-
mulate incorrect hypotheses and researchers may misin-
terpret data based on earlier definitions.
The problem is particularly important in the case of
precision medicine and personalized treatments. For
example, one of the main reasons to sequence the
genome of a cancer consists in the identification of
unique genetic features of cancer cells which may
then be targeted with a personalized treatment [41].
Accordingly, it is required to classify the somatic mu-
tations of the cancer cells and use such knowledge to
exploit therapeutically all the differences between can-
cer and noncancerous cells. Therefore, in order to be
treated with a targeted agent a cancer patient needs
to express the target originated by the specific muta-
tion occurring in cancer cells. However, should a dif-
ference be misclassified, it becomes possible for a
polymorphism (present in all the cells of the patient)
to be taken as a somatic mutation. The result could
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be a toxic effect, since the targeted treatment will
impact both cancer and noncancerous cells carrying
the same genetic variant. This problem is prevented if
both germline and somatic cancer genomes would be
sequenced in the same patient.
Another important reason underlying the need of such
distinction is that a disease may originate with two sub-
sequent mutations according to the two-hit hypothesis
[42]. Within a population, a germline mutation (first hit)
may predispose a subset of patients to a second, somatic,
mutation whose effects will create the diseased pheno-
type [43]. In this context, in order to identify popula-
tions at risk it would be extremely helpful to distinguish
between somatic and germline mutations. For example,
multiple meningiomas occur in <10 % of meningioma
patients. A first germline mutation in the SMARCB1
gene will predispose to meningioma, but this will occur
only when a somatic mutation in the NF2 gene inter-
venes [44]. In the absence of a clear distinction between
somatic and germline variants this kind of pathogenic
discovery may be impossible.
This approach is now supported by a recent study.
Jones et al. evaluated 815 tumor-normal paired samples
coming from 15 different tumor types [45] using Next
Gene Sequencing. Library preparation was performed
with two methods, whole exome preparation and tar-
geted amplification, for 111 genes. Analyses were then
conducted either as if only the cancer tissue was
sequenced (reference human genome assembly GRch37-
lite) or taking as reference the germline DNA of the
same patient. With the first analysis, the authors
reported a very high rate of false-positive variants (31 %
and 65 % in exome and targeted libraries, respectively).
Furthermore, they identified germline mutations in 3 %
of the cancers, even if they came from a cohort without
family history (sporadic cancer). Now that the new
sequencing technologies have dramatically reduced the
cost of sequencing, precision medicine and personal
genomics require that the reference of the DNA sequen-
cing project should be obtained from the germline DNA
of the same patient.
Ongoing debate and HGVS (Human Genome Variation
Society) recommendations
The ongoing debate among scientists to resolve the
nomenclature mutation and polymorphism is a step
in the right direction. The HGVS, an alliance of 600
members from 34 countries, incorporates discussion
and recommendations to establish consensus defini-
tions and descriptions of generic terms that are ac-
cepted worldwide. Since the early 1990s, the HGVS
has been instrumental in its push to standardize the
mutation nomenclature. The recommendations of the
HGVS have been based on extensive discussions
among scientists over the years.
The papers published on this topic for the last 20 years
show that HGVS was visionary to recommend new
changes and extensions based on discoveries of relatively
complex variants. In 2002, several researchers tried to
address this nomenclature problem and the challenges
to make more inclusive definitions.A special article by
Condit et al. found that mutation had become increas-
ingly negative in connotation since its use in the bio-
logical sciences, but particularly over the course of the
20th century [22]. This negativity of the term became
entrenched with radiation experiments and the use of
atomic weapons during the IInd world war, and later with
science fiction books and movies. The paper suggested
that a better term like “variation” and “alteration” might
be useful, but its inconsistent usage in the scientific
world makes it problematic.
More recently, additional papers have highlighted the
urgency of a “consensus” guiding the selection of the
sequencing methods (data collection) and reporting.
These studies point out that the accurate classification
of pathogenic variants requires a standardized approach
and the building of data repositories including all these
data [46]. In this context, Richards et al. on the behalf of
the American College of Medical Genetics and Genom-
ics (ACMG) have noted that the terms “mutation” and
“polymorphism” often lead to confusion because of in-
correct assumptions of pathogenic and benign effects,
respectively. Thus, they recommended that both terms
be replaced by the term “variant” with the following
modifiers: (i) pathogenic, (ii) likely pathogenic, (iii) un-
certain significance, (iv) likely benign, or (v) benign [47].
Summary
Despite this rhetoric to better define the terms, there
is no consensus in research papers or HGVS recom-
mendations on how a mutation is different from a
polymorphism. The lack of a consensus is creating a
problem in the interpretation of data coming from
personal genome software analysis, as described
above. What is the reference? What is the threshold
to distinguish common from rare DNA variants? This
problem is not trivial when looking at the down-
stream effects. In fact, the term mutation is com-
monly conceived (wrongly) to carry an intrinsic
negative impact on the function of a given gene.
We propose that the term “mutation” be used to indi-
cate the result of a recent mutation event which has been
detected using as a reference the germline DNA of the
same individual. Therefore, a mutation would be a “DNA
variant” acquired over the lifetime of an organism, i.e. a
somatic mutation. In this sense, mutations are the princi-
pal causes of many diseases like cancer but are typically
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not inherited by their offspring. Alterations in the DNA of
germ cells – sperms and eggs – can be inherited by off-
spring and are currently called germline mutations. In this
case, the term mutation should be used only if the germ-
line “variant” has been detected using as a reference the
germline DNA of the same individual. While germline
mutations can also increase the likelihood of succumbing
to certain diseases, the signature of such mutations is
found in each and every cell of the offspring [48]. This is
because the original embryo (first cell in the body) is
formed through the fusion of germ cells, from where all
the somatic cells arise. So in essence, while these alter-
ations in the parents’ germ cells are appropriately termed
germline mutations, calling both somatic and germline
mutations simply “mutations” seems incongruent. The
variation of genotypes among individuals, inherited from
parents but still present in the DNA of each cell in the
body, is the classic definition of a genetic polymorphism
and we propose going back to this original definition: a
polymorphism occurs in a population when the observed
variation from individual to individual is not maintained
by recurrent mutation.
Whereas it is perhaps not unreasonable to use the
term mutation for the result of a mutation event, there
is no analogy that would imply using the term poly-
morphism for a common variant because polymorphism
is a condition found in a population, not an event. Gen-
etic polymorphism, just like any other biological poly-
morphism (e.g. the siphonophores) occurs when members
of a species differ in form [49]. When the notion that the
different forms could be genotypes rather than phenotypes
was first introduced [49], the focus was on the least fre-
quent genotype not being due to recurrent mutation, and
hence the arbitrary 1 % threshold; but a genetic locus with
Fig. 1 Nomenclature of variants according to sequencing design. In a paired approach (a), diseased (tumor) DNA and DNA from the germline
(blood, saliva, or other non-diseased tissue) have been extracted and individually sequenced and mapped against a human genome reference
assembly. If there are common variants found in both the tumor and germline DNA, they should be called germline mutations. If there are
variants found only in tumor DNA, they should be called somatic mutations. In a non-paired approach of variant detection (b), only
diseased DNA is extracted from the tissue of interest. The extracted DNA has been sequenced and mapped against a human genome
reference assembly and differences as compared with the reference will be labeled as variants
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a thousand equi-frequent alleles would be considered
extremely polymorphic. Most SNPs are tri-morphic, but
are appropriately called polymorphisms in contrast to
being mono-morphic.
Different from diseases associated with SNPs, which
are expressed in all the cells of an organism, some dis-
eases, like cancer, are caused by genetic variations typical
of a small subset of somatic cells. In order to keep the
difference between the two categories of DNA variants,
we propose a clear distinction between a SNP and a
somatic mutation. A tumor sample and a normal tissue
sample from the same individual can be sequenced for
analysis of genetic variations. For statistical and comput-
ing power, additional sequences coming from buccal
swabs or peripheral blood DNA can be used to sequence
the germline reference of a patient (paired approach).
Since the tumor samples have additional genetic changes
as compared with the specific individual’s germline refer-
ence, these changes will serve as key attributes to under-
standing the cancer of this specific individual.
It is possible that germline sequences between this indi-
vidual and others also differ, and this would constitute a
polymorphism in the population, as originally defined.
The genotypes/alleles that constitute a polymorphism
should be called variants but never, without attribute, sim-
ply “mutations”. In our proposal, the term “mutation”
should be used only if the sequencing project used the
germline reference (Fig. 1a). In this context, in order to
have a mutation it is not only required to detect a vari-
ation as compared with the reference, but also the refer-
ence needs to be represented by the germline cells of the
same individual. Accordingly, the term “mutation” should
always be accompanied by a qualifying prefix indicating if
the “mutation” occurs only in somatic cells (somatic mu-
tation) or also in the germ line cells (germline mutation)
(Fig. 1a). This would prevent mutations and polymor-
phisms from being incorrectly annotated in a sequencing
project, with potential deleterious effects on the efficacy of
genomics applied to precision medicine, as recently
highlighted in recent studies [45–47].
In the case a sequencing project did not include as
a reference the germ-line DNA of an individual, the
term “mutation” could not be used and should be re-
placed by the neutral term “variant” (Fig. 1b), as pre-
viously suggested [47]. Therefore, in the sequencing
report the alternative use of the term “mutation” or
“variant” will also clarify which kind of reference was
adopted. We anticipate that this approach will encourage
the use of referencing germline DNA in a sequencing pro-
ject and will allow an immediate comparison between
studies that used the same referencing method. Import-
antly, the term “polymorphism” should only be used in
the context of a population. Accordingly, this term cannot
be approved to classify variants in personal genomics.
Abbreviations
SNP: Single nucleotide polymorphism; HGVS: Human Genome Variation
Society.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RK, DP, RCE and CF conceived and wrote the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
We thank Dr. Oliver Schildgen for prompting us to write this white paper
aimed at forming a consensus of these terms and editing some portions of
the manuscript. We also thank all the participants of the Research Gate
thread for the useful and stimulating contributions, which we have tried to
summarize in this manuscript.
Author details
1Danbury Hospital Research Institute, Western Connecticut Health Network,
131 West Street, Danbury, CT 06810, USA. 2Department of Epidemiology and
Biostatistics, Case Western Reserve University School of Medicine, Cleveland,
OH, USA.
Received: 2 October 2014 Accepted: 6 July 2015
References
1. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The
sequence of the human genome. Science. 2001;291:1304–51.
2. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial
sequencing and analysis of the human genome. Nature. 2001;409:860–921.
3. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, et al. The diploid
genome sequence of an individual human. PLoS Biol. 2007;5:e254.
4. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G,
et al. A map of human genome sequence variation containing 1.42 million
single nucleotide polymorphisms. Nature. 2001;409:928–33.
5. Schneider JA, Pungliya MS, Choi JY, Jiang R, Sun XJ, Salisbury BA, et al. DNA
variability of human genes. Mech Ageing Dev. 2003;124:17–25.
6. Jorde LB, Wooding SP. Genetic variation, classification and ‘race’. Nat Genet.
2004;36:S28–33.
7. Tishkoff SA, Kidd KK. Implications of biogeography of human populations
for ‘race’ and medicine. Nat Genet. 2004;36:S21–7.
8. Lander ES. Initial impact of the sequencing of the human genome. Nature.
2011;470:187–97.
9. Gonzaga-Jauregui C, Lupski JR, Gibbs RA. Human genome sequencing in
health and disease. Annu Rev Med. 2012;63:35–61.
10. Metzker ML. Emerging technologies in DNA sequencing. Genome Res.
2005;15:1767–76.
11. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet.
2010;11:31–46.
12. Kircher M, Kelso J. High-throughput DNA sequencing–concepts and
limitations. Bioessays. 2010;32:524–36.
13. What is the difference between polymorphism and a mutation?
[http://www.researchgate.net/post/What_is_the_difference_between_
polymorphism_and_a_mutation]
14. Cordero P, Ashley EA. Whole-genome sequencing in personalized
therapeutics. Clin Pharmacol Ther. 2012;91:1001–9.
15. Shendure J, Lieberman Aiden E. The expanding scope of DNA sequencing.
Nat Biotechnol. 2012;30:1084–94.
16. Boyd SD. Diagnostic applications of high-throughput DNA sequencing.
Annu Rev Pathol. 2013;8:381–410.
17. Knoppers BM, Senecal K, Borry P, Avard D. Whole-genome sequencing in
newborn screening programs. Sci Transl Med. 2014;6:229cm222.
18. Landau YE, Lichter-Konecki U, Levy HL. Genomics in newborn screening.
J Pediatr. 2014;164:14–9.
19. Snyder MW, Simmons LE, Kitzman JO, Santillan DA, Santillan MK, Gammill
HS, et al. Noninvasive fetal genome sequencing: a primer. Prenat Diagn.
2013;33:547–54.
20. Beaudet AL, Tsui LC. A suggested nomenclature for designating mutations.
Hum Mutat. 1993;2:245–8.
Karki et al. BMC Medical Genomics  (2015) 8:37 Page 6 of 7
21. Beutler E. The designation of mutations. Am J Hum Genet. 1993;53:783–5.
22. Condit CM, Achter PJ, Lauer I, Sefcovic E. The changing meanings of
“mutation:” A contextualized study of public discourse. Hum Mutat.
2002;19:69–75.
23. Vissers LE, de Vries BB, Osoegawa K, Janssen IM, Feuth T, Choy CO, et al.
Array-based comparative genomic hybridization for the genomewide
detection of submicroscopic chromosomal abnormalities. Am J Hum Genet.
2003;73:1261–70.
24. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al.
Detection of large-scale variation in the human genome. Nat Genet.
2004;36:949–51.
25. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, et al.
Large-scale copy number polymorphism in the human genome. Science.
2004;305:525–8.
26. Brookes AJ. The essence of SNPs. Gene. 1999;234:177–86.
27. Aerts J, Wetzels Y, Cohen N, Aerssens J. Data mining of public SNP
databases for the selection of intragenic SNPs. Hum Mutat. 2002;20:162–73.
28. Lee EK, Gorospe M. Coding region: the neglected post-transcriptional code.
RNA Biol. 2011;8:44–8.
29. Chanock S. Candidate genes and single nucleotide polymorphisms (SNPs)
in the study of human disease. Dis Markers. 2001;17:89–98.
30. Schildgen V, Schildgen O. How is a molecular polymorphism defined?
Cancer. 2013;119:1608.
31. Auer PL, Johnsen JM, Johnson AD, Logsdon BA, Lange LA, Nalls MA, et al.
Imputation of exome sequence variants into population- based samples
and blood-cell-trait-associated loci in African Americans: NHLBI GO Exome
Sequencing Project. Am J Hum Genet. 2012;91:794–808.
32. Myles S, Davison D, Barrett J, Stoneking M, Timpson N. Worldwide
population differentiation at disease-associated SNPs. BMC Med Genomics.
2008;1:22.
33. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Williams TN, et al.
Global distribution of the sickle cell gene and geographical confirmation of
the malaria hypothesis. Nat Commun. 2010;1:104.
34. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev
Med. 2010;38:S512–21.
35. Lanclos KD, Oner C, Dimovski AJ, Gu YC, Huisman TH. Sequence variations
in the 5’ flanking and IVS-II regions of the G gamma- and A gamma-globin
genes of beta S chromosomes with five different haplotypes. Blood.
1991;77:2488–96.
36. Oner C, Dimovski AJ, Olivieri NF, Schiliro G, Codrington JF, Fattoum S, et al.
Beta S haplotypes in various world populations. Hum Genet. 1992;89:99–104.
37. Lapoumeroulie C, Dunda O, Ducrocq R, Trabuchet G, Mony-Lobe M, Bodo
JM, et al. A novel sickle cell mutation of yet another origin in Africa: the
Cameroon type. Hum Genet. 1992;89:333–7.
38. Salih NA, Hussain AA, Almugtaba IA, Elzein AM, Elhassan IM, Khalil EA, et al.
Loss of balancing selection in the betaS globin locus. BMC Med Genet.
2010;11:21.
39. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med.
2010;363:2339–50.
40. Consortium TEP. An integrated encyclopedia of DNA elements in the
human genome. Nature. 2012;489:57–74.
41. Tuxen IV, Jonson L, Santoni-Rugiu E, Hasselby JP, Nielsen FC, Lassen U.
Personalized oncology: genomic screening in phase 1. Apmis.
2014;122:723–33.
42. Knudson Jr AG. Mutation and cancer: statistical study of retinoblastoma.
Proc Natl Acad Sci U S A. 1971;68:820–3.
43. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer.
2001;1:157–62.
44. Christiaans I, Kenter SB, Brink HC, van Os TA, Baas F, van den Munckhof P,
et al. Germline SMARCB1 mutation and somatic NF2 mutations in familial
multiple meningiomas. J Med Genet. 2011;48:93–7.
45. Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR,
et al. Personalized genomic analyses for cancer mutation discovery and
interpretation. Sci Transl Med. 2015;7:283ra253.
46. MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis
GR, et al. Guidelines for investigating causality of sequence variants in
human disease. Nature. 2014;508:469–76.
47. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al.
Standards and guidelines for the interpretation of sequence variants:
a joint consensus recommendation of the American College of Medical
Genetics and Genomics and the Association for Molecular Pathology.
Genet Med. 2015;17:405–23.
48. Hoenigsberg H. Cell biology, molecular embryology, Lamarckian and
Darwinian selection as evolvability. Genet Mol Res. 2003;2:7–28.
49. Ford EB. Polymorphism and taxonomy. Oxford: Clarendon; 1940.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Karki et al. BMC Medical Genomics  (2015) 8:37 Page 7 of 7
